Notably, for the two patients with more acalabrutinib-sensitive disease (MCL#0491 and MCL#0557), there was a noticeable decrease in the mass of MCL cells during BTK inhibition compared to the pretreatment state (Fig. 4B). This evidence concerns the gene BTK and mantle cell lymphoma.